Honest feedback about Teva Respiratory

Quote

























Albuterol goes generic at the end of the year, you already have several OTC nasal sprays and Nasonex is generic and generic ICS and combo are about a year away. Yep, that pretty much sums it up.
 








Sadly, Teva Respiratory is heading for a cliff. Pro-Air is going generic this coming December which means insurance companies will require it first line, not the newer ProAir Respiclick. They are trying to convince us that the two companies making the Pro-Air generic are behind but other info does not support that claim. All focus is now on the Respiclick, however, after being out for a year now, roughly 80% of all scripts are from the free vouchers. The insurance coverage is horrible in most parts of the country as they do not want to discount it. Because of this, most insurance companies are going with Ventolin or sticking with the original Pro-Air (as they know the generic is coming). We are nowhere close to where we should be one year post launch and are falling further behind each month. Most of us believe a layoff is coming in the next year unless a miracle occurs. Qnasl is up against three good nasal steroids which you can now buy over the counter, so in most cases the insurance companies won't touch it without a multi-step prior auth. Qvar is doing well at the moment, however, the HFA propellant made by 3M goes generic next January. This means anyone can make a generic Qvar as Beclomethasone (the active ingredient) has been generic for years. So there you have it, all three products have significant problems that are growing by the month. It gets worse... if you look at the pipeline, the next two products are Flovent and Advair in the respiclick device. The irony is that around the same time these two products launch, there are multiple generic versions of both that will be available. Which one do you think the insurance will cover? the higher priced branded Teva version or the cheaper generic? To add insult to injury, we have been telling doctors for years how much better Qvar is compared to Flovent. Now we will have to go back into those same doctors and say we are putting Qvar on the back burner now and moving Flovent and Advair equivalents to the front. Sound like fun?

If you are about to lose your house and need a job for a few months, then maybe it makes sense to apply. If you are looking for something a little more stable, I would keep looking. I am currently looking elsewhere myself as the writing is on the wall for Teva Respiratory's future.
 








Spot on.

anonymous said:
Sadly, Teva Respiratory is heading for a cliff. Pro-Air is going generic this coming December which means insurance companies will require it first line, not the newer ProAir Respiclick. They are trying to convince us that the two companies making the Pro-Air generic are behind but other info does not support that claim. All focus is now on the Respiclick, however, after being out for a year now, roughly 80% of all scripts are from the free vouchers. The insurance coverage is horrible in most parts of the country as they do not want to discount it. Because of this, most insurance companies are going with Ventolin or sticking with the original Pro-Air (as they know the generic is coming). We are nowhere close to where we should be one year post launch and are falling further behind each month. Most of us believe a layoff is coming in the next year unless a miracle occurs. Qnasl is up against three good nasal steroids which you can now buy over the counter, so in most cases the insurance companies won't touch it without a multi-step prior auth. Qvar is doing well at the moment, however, the HFA propellant made by 3M goes generic next January. This means anyone can make a generic Qvar as Beclomethasone (the active ingredient) has been generic for years. So there you have it, all three products have significant problems that are growing by the month. It gets worse... if you look at the pipeline, the next two products are Flovent and Advair in the respiclick device. The irony is that around the same time these two products launch, there are multiple generic versions of both that will be available. Which one do you think the insurance will cover? the higher priced branded Teva version or the cheaper generic? To add insult to injury, we have been telling doctors for years how much better Qvar is compared to Flovent. Now we will have to go back into those same doctors and say we are putting Qvar on the back burner now and moving Flovent and Advair equivalents to the front. Sound like fun?

If you are about to lose your house and need a job for a few months, then maybe it makes sense to apply. If you are looking for something a little more stable, I would keep looking. I am currently looking elsewhere myself as the writing is on the wall for Teva Respiratory's future.
Click to expand...
 








ditto about the company's future. no matter how big the rah-rah speeches from marketing and senior mgt at the pending product launch meetings, we will be competing with generic alternatives and/or Teva will be unwilling to pay the branded discounts/kickbacks demanded by the payers. as of august 2016, blue shield of California (massive payer in CA) is demoting ProAir Respilick to non-preferred. thanks Teva.
 








































anonymous said:
Sadly, Teva Respiratory is heading for a cliff. Pro-Air is going generic this coming December which means insurance companies will require it first line, not the newer ProAir Respiclick. They are trying to convince us that the two companies making the Pro-Air generic are behind but other info does not support that claim. All focus is now on the Respiclick, however, after being out for a year now, roughly 80% of all scripts are from the free vouchers. The insurance coverage is horrible in most parts of the country as they do not want to discount it. Because of this, most insurance companies are going with Ventolin or sticking with the original Pro-Air (as they know the generic is coming). We are nowhere close to where we should be one year post launch and are falling further behind each month. Most of us believe a layoff is coming in the next year unless a miracle occurs. Qnasl is up against three good nasal steroids which you can now buy over the counter, so in most cases the insurance companies won't touch it without a multi-step prior auth. Qvar is doing well at the moment, however, the HFA propellant made by 3M goes generic next January. This means anyone can make a generic Qvar as Beclomethasone (the active ingredient) has been generic for years. So there you have it, all three products have significant problems that are growing by the month. It gets worse... if you look at the pipeline, the next two products are Flovent and Advair in the respiclick device. The irony is that around the same time these two products launch, there are multiple generic versions of both that will be available. Which one do you think the insurance will cover? the higher priced branded Teva version or the cheaper generic? To add insult to injury, we have been telling doctors for years how much better Qvar is compared to Flovent. Now we will have to go back into those same doctors and say we are putting Qvar on the back burner now and moving Flovent and Advair equivalents to the front. Sound like fun?

If you are about to lose your house and need a job for a few months, then maybe it makes sense to apply. If you are looking for something a little more stable, I would keep looking. I am currently looking elsewhere myself as the writing is on the wall for Teva Respiratory's future.
Click to expand...
 








The Southeast, currently with another Respiratory company that's being acquired, thought Teva might be a good fit. I had no idea there was so much turmoil here...not what management is saying.
 
































































Top Bottom
Back
Quote